Measuring improvement in populations: Implementing and evaluating successful change in lung cancer care

Translational Lung Cancer Research

Volumn 4, Issue 4, 2015, Pages 373-384

  Yu, Xinhua ^a   Klesges, Lisa M ^a   Smeltzer, Mathew P ^a   Osarogiagbon, Raymond U ^b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b BAPTIST CANCER CENTER   (United States)

Author keywords

Dissemination and implementation; Evidence based practice; Health services research; Quality improvement

Indexed keywords

CANCER MORTALITY; EVALUATION STUDY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; LUNG CANCER; OBSERVATIONAL STUDY; PATIENT CARE; PRACTICE GUIDELINE; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOTAL QUALITY MANAGEMENT; UNITED STATES;

EID: 84960094540     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2015.07.13     Document Type: Review

References (77)

1. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press, 2001.
2. Institute of Medicine. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC: The National Academies Press, 2013.
3. Donabedian A. The quality of care. How can it be assessed? JAMA 1988;260:1743-8.
4. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA 1998;280:1000-5.
5. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med 2000;51:1611-25.
6. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes. 4th ed. Chicago: Health Administration Press, 2013.
7. American Cancer Society. Learn About Cancer? Lung Cancer-Non-Small Cell. [Accessed June 28, 2015]. Available online: http://www.cancer.org/cancer/lungcancer-non-smallcell/index
8. Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008;26:3631-7.
9. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341:1198-205.
10. Lathan CS, Neville BA, Earle CC. Racial composition of hospitals: effects on surgery for early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:4347-52.
11. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 2003;15:523-30.
12. Tanvetyanon T. Quality-of-care indicators for non-small cell lung cancer. Cancer Control 2009;16:335-41.
13. Mazzone PJ, Vachani A, Chang A, et al. Quality indicators for the evaluation of patients with lung cancer. Chest 2014;146:659-69.
14. Hermens RP, Ouwens MM, Vonk-Okhuijsen SY, et al. Development of quality indicators for diagnosis and treatment of patients with non-small cell lung cancer: a first step toward implementing a multidisciplinary, evidence-based guideline. Lung Cancer 2006;54:117-24.
15. Tanvetyanon T, Corman M, Lee JH, et al. Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract 2011;7:e25-31.
16. Darling G, Malthaner R, Dickie J, et al. Quality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus process. Ann Thorac Surg 2014;98:183-90.
17. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Small Cell Lung Cancer (version 3.2015). [Accessed June 28, 2015]. Available online: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
18. CoC Quality of Care Measures. CoC Measures for Quality of Cancer Care-Non-Small Cell Lung Cancer. [Accessed June 28, 2015]. Available online: https://www.facs.org/quality%20programs/cancer/ncdb/qualitymeasures
19. Farjah F, Flum DR, Ramsey SD, et al. Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol 2009;4:355-63.
20. Osarogiagbon RU, Darling GE. Towards optimal pathologic staging of resectable non-small cell lung cancer. Transl Lung Cancer Res 2013;2:364-71.
21. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662-70.
22. Osarogiagbon RU, Yu X. Mediastinal lymph node examination and survival in resected early-stage non-smallcell lung cancer in the surveillance, epidemiology, and end results database. J Thorac Oncol 2012;7:1798-806.
23. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. Thorax 2009;64:749-56.
24. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. Thorax 1998;53 Suppl 1:S1-8.
25. Billing JS, Wells FC. Delays in the diagnosis and surgical treatment of lung cancer. Thorax 1996;51:903-6.
26. Faris N, Yu X, Sareen S, et al. Preoperative Evaluation of Lung Cancer in a Community Health Care Setting. Ann Thorac Surg 2015;100:394-400.
27. Gomez DR, Liao KP, Swisher SG, et al. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiother Oncol 2015;115:257-63.
28. Quarterman RL, McMillan A, Ratcliffe MB, et al. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;125:108-13; discussion 113-4.
29. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax 2004;59:45-9.
30. Salomaa ER, Sällinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung cancer. Chest 2005;128:2282-8.
31. Lennes IT, Lynch TJ. Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. Clin Lung Cancer 2009;10:341-6.
32. Kane RL, Radosevich DM. Conducting health outcomes research. Sudbury, Mass.: Jones & Bartlett Learning, 2011.
33. Green A, Hauge J, Iachina M, et al. The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. Eur J Cardiothorac Surg 2015. [Epub ahead of print].
34. Pezzi CM, Mallin K, Mendez AS, et al. Ninetyday mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg 2014;148:2269-77.
35. Hu Y, McMurry TL, Isbell JM, et al. Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. J Thorac Cardiovasc Surg 2014;148:2261-7.e1.
36. Sanson-Fisher RW, D'Este CA, Carey ML, et al. Evaluation of systems-oriented public health interventions: alternative research designs. Annu Rev Public Health 2014;35:9-27.
37. Green LW, Glasgow RE. Evaluating the relevance, generalization, and applicability of research: issues in external validation and translation methodology. Eval Health Prof 2006;29:126-53.
38. Peek CJ, Glasgow RE, Stange KC, et al. The 5 R's: an emerging bold standard for conducting relevant research in a changing world. Ann Fam Med 2014;12:447-55.
39. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32.
40. Brownson RC, Colditz GA, Proctor EK, editors. Dissemination and implementation research in health: translating science to practice. New York: Oxford University Press, 2012.
41. Lobb R, Colditz GA. Implementation science and its application to population health. Annu Rev Public Health 2013;34:235-51.
42. Gaglio B, Phillips SM, Heurtin-Roberts S, et al. How pragmatic is it? Lessons learned using PRECIS and REAIM for determining pragmatic characteristics of research. Implement Sci 2014;9:96.
43. Tabak RG, Khoong EC, Chambers DA, et al. Bridging research and practice: models for dissemination and implementation research. Am J Prev Med 2012;43:337-50.
44. Dissemination & Implementation Models in Health Research & Practice. [Accessed July 10, 2015]. Available online: http://dissemination-implementation.org/viewAll_di.aspx
45. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-75.
46. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the REAIM framework. Am J Public Health 1999;89:1322-7.
47. Gaglio B, Shoup JA, Glasgow RE. The RE-AIM framework: a systematic review of use over time. Am J Public Health 2013;103:e38-46.
48. Dzewaltowski DA, Glasgow RE, Klesges LM, et al. REAIM: evidence-based standards and a Web resource to improve translation of research into practice. Ann Behav Med 2004;28:75-80.
49. Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf 2008;34:228-43.
50. Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci 2015;10:53.
51. Glanz K, Rimer BK, Viswanath K, editors. Health Behavior and Health Education: Theory, Research, and Practice. 4th ed. San Francisco: Jossey-Bass, 2008.
52. Klesges LM, Estabrooks PA, Dzewaltowski DA, et al. Beginning with the application in mind: designing and planning health behavior change interventions to enhance dissemination. Ann Behav Med 2005;29 Suppl:66-75.
53. Eccles M, Grimshaw J, Walker A, et al. Changing the behavior of healthcare professionals: the use of theory in promoting the uptake of research findings. J Clin Epidemiol 2005;58:107-12.
54. French SD, Green SE, O'Connor DA, et al. Developing theory-informed behaviour change interventions to implement evidence into practice: a systematic approach using the Theoretical Domains Framework. Implement Sci 2012;7:38.
55. Glasgow RE, Chambers D. Developing robust, sustainable, implementation systems using rigorous, rapid and relevant science. Clin Transl Sci 2012;5:48-55.
56. Abernethy AP, Etheredge LM, Ganz PA, et al. Rapid-learning system for cancer care. J Clin Oncol 2010;28:4268-74.
57. Murray DM, Pennell M, Rhoda D, et al. Designing studies that would address the multilayered nature of health care. J Natl Cancer Inst Monogr 2010;2010:90-6.
58. Hayes RJ, Moulton LH. Cluster Randomised Trials (Chapman & Hall/CRC Biostatistics Series). Boca Raton: Chapman and Hall/CRC, 2009.
59. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 2007;28:182-91.
60. Hemming K, Haines TP, Chilton PJ, et al. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ 2015;350:h391.
61. Hemming K, Girling A, Martin J, et al. Stepped wedge cluster randomized trials are efficient and provide a method of evaluation without which some interventions would not be evaluated. J Clin Epidemiol 2013;66:1058-9.
62. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006;6:54.
63. Hemming K, Lilford R, Girling AJ. Stepped-wedge cluster randomised controlled trials: a generic framework including parallel and multiple-level designs. Stat Med 2015;34:181-96.
64. Moulton LH, Golub JE, Durovni B, et al. Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 2007;4:190-9.
65. Hawkins NG, Sanson-Fisher RW, Shakeshaft A, et al. The multiple baseline design for evaluating population-based research. Am J Prev Med 2007;33:162-8.
66. McHugh M, Harvey JB, Kang R, et al. Community-Level Quality Improvement and the Patient Experience for Chronic Illness Care. Health Serv Res 2015. [Epub ahead of print].
67. Kotz D, Spigt M, Arts IC, et al. Use of the stepped wedge design cannot be recommended: a critical appraisal and comparison with the classic cluster randomized controlled trial design. J Clin Epidemiol 2012;65:1249-52.
68. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. 2nd ed. Belmont: Wadsworth Publishing, 2001.
69. Handley MA, Schillinger D, Shiboski S. Quasiexperimental designs in practice-based research settings: design and implementation considerations. J Am Board Fam Med 2011;24:589-96.
70. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2008.
71. Allen JW, Farooq A, O'Brien TF, et al. Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. Cancer 2011;117:134-42.
72. Ramirez RA, Wang CG, Miller LE, et al. Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer. J Clin Oncol 2012;30:2823-8.
73. Osarogiagbon RU, Ramirez RA, Wang CG, et al. Dual intervention to improve pathologic staging of resectable lung cancer. Ann Thorac Surg 2013;96:1975-81.
74. Osarogiagbon RU, Miller LE, Ramirez RA, et al. Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer. J Thorac Oncol 2012;7:1276-82.
75. Detterbeck F. What is quality and does it matter? J Thorac Oncol 2009;4:279-80.
76. Osarogiagbon RU, Ogbata O, Yu X. Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer. Ann Thorac Surg 2014;97:385-93.
77. Jung K. The impact of information disclosure on quality of care in HMO markets. Int J Qual Health Care 2010;22:461-8.